89483-08-9

Basic information

• Product Name: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid
• Synonyms: (R)-2-(Boc-amino)-3-cyclopropylpropionic acid;N-Boc-R-3-Cyclopropylalanine
• CAS NO: 89483-08-9
• Molecular Formula: C11H19NO4
• Molecular Weight: 229.27286
• Mol File: 89483-08-9.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(89483-08-9)
• EPA Substance Registry System: (R)-2-((tert-butoxycarbonyl)aMino)-3-cyclopropylpropanoic acid(89483-08-9)

Safety Data

• Hazardous Substances Data: 89483-08-9(Hazardous Substances Data)

Usage

General Description

"(R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid" is a compound that belongs to the class of organic compounds known as N-acyl-alpha amino acids. It is a derivative of L-alanine and is commonly used as a building block in the synthesis of various peptides and other biologically active compounds. The compound is also known for its potential therapeutic properties, including anti-inflammatory and analgesic effects. Its molecular structure consists of a cyclopropyl group, an amino group protected by a tert-butoxycarbonyl group, and a carboxylic acid group, making it a versatile and important chemical in the field of medicinal chemistry and pharmaceutical research.

Upstream product

• 33574-02-6 cyclopropylmethyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 170115-96-5 2-amino-N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methylacetamide 
• 170642-22-5 (R)-2-Amino-3-cyclopropyl-N-((1S,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-N-methyl-propionamide 
• 121786-39-8 (R)-2-amino-3-cyclopropylpropanoic acid 
• 34619-03-9 tert-butyldicarbonate 
• 104347-84-4 methyl (S)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoate 
• 102735-53-5 (2S)-2-amino-3-cyclopropylpropanoic acid 

Relevant articles and documents

TRIAZOLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS

This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).

Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation

The discovery of natural specialized pro-resolving mediators and their corresponding receptors, such as formyl peptide receptor 2 (FPR2), indicated that resolution of inflammation (RoI) is an active process which could be harnessed for innovative approaches to tame pathologies with underlying chronic inflammation. In this work, homology modelling, molecular docking and pharmacophore studies were deployed to assist the rationalization of the structure-activity relationships of known FPR2 agonists. The developed pharmacophore hypothesis was then used in parallel with the homology model for the design of novel ligand structures and in virtual screening. In the first round of optimization compound 8, with a cyclopentane core, was chosen as the most promising agonist (β-arrestin recruitment EC50 = 20 nM and calcium mobilization EC50 = 740 nM). In a human neutrophil static adhesion assay, compound 8 decreased the number of adherent neutrophils in a concentration dependent manner. Further investigation led to the more rigid cycloleucines (compound 22 and 24) with improved ADME profiles and maintaining FPR2 activity. Overall, we identified novel cyclopentane urea FPR2 agonists with promising ADMET profiles and the ability to suppress the inflammatory process by inhibiting the neutrophil adhesion cascade, which indicates their anti-inflammatory and pro-resolving properties.

ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS

The present invention provides cyclic depsipeptide compounds of formula (I) and compositions comprising the compounds that are effective against parasites that harm animals, including humans. The compounds and compositions may be used for combating parasites in or on animals including mammals and birds. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation in animals, including birds and mammals.